Brian Rini

Chief of Clinical Trials

Vanderbilt University Medical Center

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Brian Rini is the Chief of Clinical Trials at Vanderbilt University Medical Center in the United States. His research primarily focuses on renal cell carcinoma, encompassing areas such as the safety and efficacy of immunotherapy and targeted treatments. He has contributed significantly to the understanding of patient outcomes and biomarkers in renal cancer, as evidenced by his recent publications.

Articles (10)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Collaborators (4)

David Braun

Assistant Professor, Principal Investigator

Yale University Yale Cancer Center

UNITED STATES

View details

Hideaki Miyake

JAPAN

View details

James Brugarolas

Professor

University of Texas Southwestern Medical Center

UNITED STATES

View details

Scott Haake

Assistant Professor

Vanderbilt University Medical Center

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Brian Rini

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Biomarker-informed care for patients with renal cell carcinoma

The safety profile of belzutifan in renal tumors: real-world data from a tertiary academic center

Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial

Circulating kidney injury molecule-1 (KIM-1) and association with outcome to adjuvant immunotherapy in renal cell carcinoma

An Oncologist's Perspective on Kidney Cancer Research Over the Last 25 Years

Integrative Analyses of Tumor and Peripheral Biomarkers in the Treatment of Advanced Renal Cell Carcinoma

A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma

Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial

Efficacy of avelumab plus axitinib versus sunitinib by numbers of IMDC risk factors and target tumor sites at baseline in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101

Navigating and adapting care integrating immunotherapy, antiangiogenic therapy, and combinations in patients with advanced renal cell carcinoma

Collaborators (4)

David Braun

Hideaki Miyake

James Brugarolas

Scott Haake

Make your next move.